Bli medlem
Bli medlem

Du är här

2016-05-09

Apricus Biosciences, Inc.: Apricus Biosciences Provides Corporate Update and First Quarter Financial Results

Vitaros® U.S. NDA Re-Submission on Schedule for 3Q 2016

SAN DIEGO, May 09, 2016 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc.
(Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in
urology and rheumatology, today reported financial results for the first
quarter of 2016 and provided a corporate update on its priorities for 2016.
Apricus will hold a previously announced webcast this morning at 8:00 am PDT
with Edward D. Kim, M.D., a member of the Company's Scientific Advisory Board
and a Vitaros® clinical investigator, to discuss the Vitaros opportunity as
part of the Company's corporate activities concurrent with the American
Urological Association's 2016 Annual Meeting, May 6 - 10 in San Diego.
Please join the webcast at www.apricusbio.com to view the presentation slides
or, to participate by telephone, dial (877) 841-3961 (Domestic) or (201)
689-8589 (International). The conference ID number is 13633850.

"In March, we sharpened our focus on growth of the Vitaros brand, as we
streamlined our organization in an effort to align our corporate strategy and
our financial resources with the goal of achieving profitability in 2017,"
stated Richard W. Pascoe, Chief Executive Officer. "Importantly, we
experienced record Vitaros royalties in Europe in the first quarter of 2016
and we continue to have a productive dialogue with the Food and Drug
Administration ("FDA") regarding the Vitaros New Drug Application ("NDA")
resubmission content and format. As such, we remain on track to resubmit the
NDA for Vitaros U.S. in the third quarter of 2016 with an approval decision
expected after a six month review period. Finally, we will continue to work
closely with our partners to grow Vitaros revenue by supporting additional
regulatory approvals and launches, licensing additional territories, and
leveraging our existing partnerships to help ensure Vitaros is actively
commercialized in all approved territories."

First Quarter Highlights and Recent Developments

Apricus recently updated its corporate goals to focus on increasing Vitaros'
value through the fostering and expansion of its commercial partnerships, in
the U.S. and globally, and strengthening the Company's financial position.
First quarter and recent highlights include:

* Closed on a $10 million registered direct offering with certain
institutional investors, including existing investors Sarissa Capital and
Aspire Capital;
* Reported top-line Phase 2b data for fispemifene in symptomatic secondary
hypogonadism that failed to achieve statistical significance in key
clinical benefit endpoints and abandoned further clinical activities
surrounding fispemifene; and
* Expanded the Company's exclusive distribution agreement with Ferring
Pharmaceuticals to market Vitaros in the United Kingdom as part of the
Company's ongoing initiative to consolidate Vitaros territories with
existing partners in an effort to maximize efficiencies and revenue.

2016 Priorities

Apricus is focused on achieving the following key strategic objectives:

Vitaros®*
(alprostadil)

* Continue implementation of the U.S. regulatory approval strategy to address
the safety and manufacturing issues raised by the FDA in the original
Vitaros NDA submission, with an NDA resubmission on target for the third
quarter of 2016;
* Continue to support the Company's ex-U.S. partners' efforts to increase
revenue in countries where partners have launched Vitaros, seek solutions
to ensure that Vitaros is available to patients in every country where it
is approved but not currently marketed, support new commercial launches by
the Company's partners and assist the Company's partners in obtaining
additional regulatory approvals in their respective territories; and
* Continue to generate the required data in 2016 to support delivery device
improvements and related regulatory submission(s) with a priority to
support the U.S. NDA resubmission of the refrigerated version of Vitaros.

RayVa(TM)
(alprostadil)

* Complete the formulation development for at-home dosing;
* Finalize the Phase 2b study protocol;
* Explore Orphan Drug Designation in the U.S. and EU; and
* Explore global or regional partnerships prior to initiating the Phase 2b
study.

First Quarter Financial Results

Revenue during the quarter ended March 31, 2016 was $0.6 million, compared to
revenue of $0.5 million during the first quarter of 2015. Revenue during the
quarter ended March 31, 2016 was comprised of $0.4 million in royalty
revenues, an increase of $0.3 million or 317% over the quarter ended March
31, 2015. Revenue during the quarter ended March 31, 2015 included $0.4
million in license fee revenue related to the expansion of the Company's
license agreement with Sandoz to commercialize Vitaros in certain Asian and
Pacific countries. Basic net loss for the quarter ended March 31, 2016 was
$2.5 million, or basic loss per share of $0.05, compared to a net loss of
$6.4 million, or $0.13 per share for the first quarter of 2015. Reducing the
net loss for the quarter ended March 31, 2016 was a non-cash change in the
fair value of the Company's warrant liability in the amount of $2.6 million.

As of March 31, 2016, cash and cash equivalents totaled $6.9 million, compared
to $3.9 million as of December 31, 2015.

2016 Financial Outlook

Early in the second quarter of 2016, Apricus reduced its staff, including the
executive team, by approximately 30%, decreased the size of the Board by one
member and reduced the Board's cash compensation. Apricus plans to continue
to reduce operating expenses (excluding non-cash stock-based compensation
expense and depreciation expense), with a goal of achieving reductions of
approximately 30% in 2016 and 60% in 2017 as compared to 2015 operating
expenses (excluding non-cash stock-based compensation expense and
depreciation expense).

In 2016, Apricus expects to continue to generate cash from milestone or
licensing payments and royalty revenues from its partners' sales of Vitaros.
Apricus will also continue to pursue out-licensing opportunities for Vitaros
in Asia-Pacific. Apricus' expenditures will include minimal costs for the
preparatory Phase 2b clinical development of RayVa, as well as costs for
activities associated with supporting the regulatory approval of Vitaros in
the U.S. and the commercialization of Vitaros in Europe.

About Apricus Biosciences, Inc.

Apricus Biosciences, Inc. (APRI) is a biopharmaceutical company advancing
innovative medicines in urology and rheumatology. Apricus' commercial
product, Vitaros®, for the treatment of erectile dysfunction, is approved in
Europe and Canada and is being commercialized in several countries in Europe.
In September 2015, Apricus in-licensed the U.S. development and
commercialization rights for Vitaros from Allergan. Apricus' marketing
partners for Vitaros include Laboratoires Majorelle, Bracco S.p.A., Hexal AG
(Sandoz), Recordati Ireland Ltd. (Recordati S.p.A.), Ferring International
Center S.A. (Ferring Pharmaceuticals), Mylan NV and Elis Pharmaceuticals Ltd.
Apricus currently has one active product candidate, RayVa(TM), its product
candidate for the treatment of the circulatory disorder Raynaud's phenomenon.

For further information on Apricus, visit http://www.apricusbio.com.

*Vitaros® is a registered trademark of NexMed International Limited. Such
trademark is registered in certain countries throughout the world and pending
registration in the United States.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act, as amended. Statements in this
press release that are not purely historical are forward-looking statements.
Such forward-looking statements include, among other things: Apricus' plans
to grow revenues for Vitaros® outside the United States, the timing of
regulatory submission and approval of Vitaros in the United States, if any;
Apricus' plans for life-cycle development programs for Vitaros; Apricus'
development and partnering plans for RayVa(TM); Apricus' plans to pursue
out-licensing opportunities for Vitaros in Asia-Pacific; Apricus' plans to
reduce operating expenses and achieve profitability, including projected 2016
and 2017 cost savings; and Apricus' 2016 strategic objectives. Actual results
could differ from those projected in any forward-looking statements due to a
variety of reasons that are outside the control of Apricus, including, but
not limited to: the risk that the cost and other negative effects related to
the reduction of Apricus' workforce may be greater than anticipated; the risk
that Apricus may not realize the benefits expected from the new strategic
focus, workforce reduction and other cost control measures; Apricus'
dependence on its commercial partners to carry out the commercial launch or
grow sales of Vitaros in various territories and the potential for delays in
the timing of commercial launches in additional countries; competition in the
erectile dysfunction market and other markets in which Apricus and its
partners operate; Apricus' ability to obtain FDA and other requisite
governmental approval for Vitaros; Apricus' ability to further develop
Vitaros, such as delivery device improvements; Apricus' ability to carry out
further clinical studies for Vitaros, if required, as well as the timing and
success of the results of such studies; Apricus' ability to achieve U.S. and
EU Orphan Designation for RayVa; Apricus' ability to retain and attract key
personnel; Apricus' ability to raise additional funding that it may need to
continue to pursue its commercial and business development plans; Apricus'
ability to remain in compliance with the terms and restrictions under the
credit facility; Apricus' ability to secure an ex-U.S. strategic partner for
RayVa and a licensing partner for Vitaros in Asia-Pacific; and market
conditions. These forward-looking statements are made as of the date of this
press release, and Apricus assumes no obligation to update the
forward-looking statements, or to update the reasons why actual results could
differ from those projected in the forward-looking statements. Readers are
urged to read the risk factors set forth in Apricus' most recent annual
report on Form 10-K, subsequent quarterly reports filed on Form 10-Q, and
other filings made with the SEC. Copies of these reports are available from
the SEC's website at www.sec.gov or without charge from Apricus.

(Financial Information to Follow)

-----------------------------------------------------------------------
| |
| Selected Financial Information |
| Condensed Consolidated Statements of Operations |
| (In thousand...

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.